López-Alvarenga J C, Sobrino-Cossío S, Remes-Troche J M, Chiu-Ugalde J, Vargas-Romero J A, Schmulson M
Research Office, Hospital General de México O.D., Mexico City, Mexico.
Rev Gastroenterol Mex. 2013 Jan-Mar;78(1):21-7. doi: 10.1016/j.rgmx.2012.10.003. Epub 2013 Feb 1.
Irritable Bowel Syndrome (IBS) is a disorder characterized by abdominal pain or discomfort associated with changes in bowel habit. Currently there are no objective outcome measures for evaluating the effectiveness of treatments for this disorder.
To determine the usefulness of a method of analysis that employs polar vectors to evaluate the effectiveness of IBS treatments.
Data from a Phase IV clinical study with 1677 active IBS-Rome III patients who received 100mg of pinaverium bromide+300mg of simethicone (PB+S) po bid for a period of four weeks were used for the analysis. Using the Bristol Stool Scale as a reference, the consistency and frequency of each type of bowel movement were recorded weekly in a Bristol Matrix (BM) and the data were expressed as polar vectors.
The analysis showed a differential response to the PB+S treatment among the IBS subtypes: in reference to the IBS with constipation subtype, the magnitude of the vector increased from 10.2 to 12.5, reaching maximum improvement at two weeks of treatment (p<0.05, Scheffé). In the IBS with diarrhea and mixed IBS subtypes, the magnitude of the vector decreased from 19 to 14 (p<0.05) and from 16.5 to 13 (p<0.05), respectively, with continuous improvement for a period of four weeks. There was no definable vectorial pattern in the unsubtyped IBS group.
Analysis with polar vectors enables treatment response to be measured in different IBS subtypes. All the groups showed improvement with PB+S, but each one had its own characteristic response in relation to vector magnitude and direction. The proposed method can be implemented in clinical studies to evaluate the efficacy of IBS treatments.
肠易激综合征(IBS)是一种以腹痛或不适并伴有排便习惯改变为特征的疾病。目前尚无用于评估该疾病治疗效果的客观结局指标。
确定一种采用极坐标向量来评估IBS治疗效果的分析方法的实用性。
来自一项IV期临床研究的数据被用于分析,该研究中有1677例活动性IBS-Rome III患者,他们口服100mg匹维溴铵+300mg西甲硅油(PB+S),每日两次,为期四周。以布里斯托大便分类法为参考,每周在布里斯托矩阵(BM)中记录每种排便类型的稠度和频率,数据以极坐标向量表示。
分析显示IBS各亚型对PB+S治疗有不同反应:相对于便秘型IBS亚型,向量大小从10.2增加到12.5,在治疗两周时达到最大改善(p<0.05,谢费检验)。在腹泻型IBS和混合型IBS亚型中,向量大小分别从19降至14(p<0.05)和从16.5降至13(p<0.05),并在四周内持续改善。未分型IBS组中没有可明确的向量模式。
用极坐标向量进行分析能够测量不同IBS亚型的治疗反应。所有组使用PB+S后均有改善,但每组在向量大小和方向方面都有其自身的特征性反应。所提出的方法可应用于临床研究以评估IBS治疗的疗效。